Gonadotropin-releasing hormone antagonists in prostate cancer

Adam S. Kittai, Jessica Blank, Julie Graff

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Androgen deprivation therapy (ADT) comes in several forms, such as surgical castration or medical castration using gonadotropin-releasing hormone (GnRH) agonist or GnRH antagonist therapy. ADT is a critical treatment for high-risk and metastatic prostate cancer. There are important differences between GnRH agonists and antagonists. Here we review the mechanism of action between GnRH agonists and antagonists and the studies that led to the approval of degarelix. We also comment on the potential risks and benefits of degarelix, particularly when it comes to cardiovascular health. Finally, we describe an oral GnRH antagonist, which is not currently used in prostate cancer, but is included for completeness.

Original languageEnglish (US)
Pages (from-to)599-606
Number of pages8
JournalONCOLOGY (United States)
Volume32
Issue number12
StatePublished - Jan 1 2018

Fingerprint

Hormone Antagonists
Gonadotropin-Releasing Hormone
Prostatic Neoplasms
Castration
Androgens
Therapeutics
Health

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gonadotropin-releasing hormone antagonists in prostate cancer. / Kittai, Adam S.; Blank, Jessica; Graff, Julie.

In: ONCOLOGY (United States), Vol. 32, No. 12, 01.01.2018, p. 599-606.

Research output: Contribution to journalReview article

Kittai, Adam S. ; Blank, Jessica ; Graff, Julie. / Gonadotropin-releasing hormone antagonists in prostate cancer. In: ONCOLOGY (United States). 2018 ; Vol. 32, No. 12. pp. 599-606.
@article{da968639611c492786a5e6572c129eb0,
title = "Gonadotropin-releasing hormone antagonists in prostate cancer",
abstract = "Androgen deprivation therapy (ADT) comes in several forms, such as surgical castration or medical castration using gonadotropin-releasing hormone (GnRH) agonist or GnRH antagonist therapy. ADT is a critical treatment for high-risk and metastatic prostate cancer. There are important differences between GnRH agonists and antagonists. Here we review the mechanism of action between GnRH agonists and antagonists and the studies that led to the approval of degarelix. We also comment on the potential risks and benefits of degarelix, particularly when it comes to cardiovascular health. Finally, we describe an oral GnRH antagonist, which is not currently used in prostate cancer, but is included for completeness.",
author = "Kittai, {Adam S.} and Jessica Blank and Julie Graff",
year = "2018",
month = "1",
day = "1",
language = "English (US)",
volume = "32",
pages = "599--606",
journal = "ONCOLOGY (United States)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "12",

}

TY - JOUR

T1 - Gonadotropin-releasing hormone antagonists in prostate cancer

AU - Kittai, Adam S.

AU - Blank, Jessica

AU - Graff, Julie

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Androgen deprivation therapy (ADT) comes in several forms, such as surgical castration or medical castration using gonadotropin-releasing hormone (GnRH) agonist or GnRH antagonist therapy. ADT is a critical treatment for high-risk and metastatic prostate cancer. There are important differences between GnRH agonists and antagonists. Here we review the mechanism of action between GnRH agonists and antagonists and the studies that led to the approval of degarelix. We also comment on the potential risks and benefits of degarelix, particularly when it comes to cardiovascular health. Finally, we describe an oral GnRH antagonist, which is not currently used in prostate cancer, but is included for completeness.

AB - Androgen deprivation therapy (ADT) comes in several forms, such as surgical castration or medical castration using gonadotropin-releasing hormone (GnRH) agonist or GnRH antagonist therapy. ADT is a critical treatment for high-risk and metastatic prostate cancer. There are important differences between GnRH agonists and antagonists. Here we review the mechanism of action between GnRH agonists and antagonists and the studies that led to the approval of degarelix. We also comment on the potential risks and benefits of degarelix, particularly when it comes to cardiovascular health. Finally, we describe an oral GnRH antagonist, which is not currently used in prostate cancer, but is included for completeness.

UR - http://www.scopus.com/inward/record.url?scp=85059625164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059625164&partnerID=8YFLogxK

M3 - Review article

C2 - 30632129

AN - SCOPUS:85059625164

VL - 32

SP - 599

EP - 606

JO - ONCOLOGY (United States)

JF - ONCOLOGY (United States)

SN - 0890-9091

IS - 12

ER -